 Shares of Arcturus Therapeutics Holdings Inc. gained 3.7 in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical trial for its COVID-19 vaccine candidate. Arcturus last week announced disappointing data from the Phase 12 trial conducted in Singapore that sent the stock tumbling 55. 